No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
273 |
4. Check minimum number of eventsNone |
273 |
5. Include endpointsNone |
273 |
6. Filter based on genotype QC (FinnGen only) |
264 |
Control definitions (FinnGen only)
- Control exclude
- G6_MYONEU
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Other and unspecified primary disorders of muscles
based on the number of shared cases.
Similar with more cases:
- Diseases of the myoneural junction and muscle
- Neurological diseases
- Neurological diseases, wide definition
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1716 | 804 | 901 |
| Only index persons | 1507 | 719 | 788 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.03 |
| Only index persons | 0.03 | 0.03 | 0.03 |
| Median age at first event (years) | |||
| Whole population | 51.52 | 52.43 | 50.70 |
| Only index persons | 51.61 | 52.14 | 51.12 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 264 | 136 | 128 |
| Unadjusted period prevalence (%) | 0.05 | 0.05 | 0.06 |
| Median age at first event (years) | 52.75 | 53.64 | 51.81 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 273
- Matched controls
- 2730
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G71.9
ICD-10 Finland
Primary disorder of muscle, unspecified
+∞
239.2
193
*
G71.8
ICD-10 Finland
Other primary disorders of muscles
+∞
116.2
103
*
G72.9
ICD-10 Finland
Myopathy, unspecified
+∞
100.4
90
*
G71.08
ICD-10 Finland
Other muscular dystrophy
+∞
73.3
67
*
R1250
NOMESCO Finland
Evaluation of functional capability
16.6
50.5
45
32
Z31.5
ICD-10 Finland
Genetic counselling
9.1
48.1
68
96
G71.18
ICD-10 Finland
Other myotonic disease
+∞
37.4
35
*
NXL00
NOMESCO Finland
Biopsy of muscle
395.3
35.8
35
*
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
7.0
35.8
63
112
L28
ICPC
Limited function/disability (L)
5.4
35.4
92
236
SPAT1229
SPAT
Assessment of need for aid
8.7
33.8
47
64
NJ3CG
NOMESCO Finland
Extensive MRI examination of extremities with median high magnet
377.8
33.7
33
*
N03AE01
ATC
clonazepam; systemic
7.4
30.7
49
78
G72.8
ICD-10 Finland
Other specified myopathies
337.8
30.4
30
*
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
7.2
28.6
47
77
NJ3BG
NOMESCO Finland
MRI examination of extremities with high intensity magnet
143.1
25.1
26
*
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
4.6
23.3
66
177
G71.00
ICD-10 Finland
Muscular dystrophy benign [Becker]
+∞
23.3
22
*
J96.1
ICD-10 Finland
Chronic respiratory failure
21.7
21.4
31
16
R13
ICD-10 Finland
Dysphagia
6.0
20.3
39
74
G71.3
ICD-10 Finland
Mitochondrial myopathy, not elsewhere classified
+∞
20.0
19
*
R4120
NOMESCO Finland
Occupational therapy
5.2
19.2
43
94
G71.11
ICD-10 Finland
Dystrophia myotonica [Steinert]
+∞
19.0
18
*
G71.0
ICD-10 Finland
Muscular dystrophy
+∞
16.8
16
*
A28
ICPC
Limited function/disability NOS
3.6
16.7
67
227
N99
ICPC
Neurological disease other
22.7
16.3
23
11
R5110, ,
SPAT
5.7
16.2
32
62
Z3226
NOMESCO Finland
Physiotherapist
3.2
16.0
82
323
G71.12
ICD-10 Finland
Myotonia congenita
+∞
15.8
15
*
M60.8
ICD-10 Finland
Other myositis
169.3
15.6
16
*
NGA20
NOMESCO Finland
Exploration of soft tissue knee or lower leg, open
169.3
15.6
16
*
XF404
NOMESCO Finland
Ambulatory ECG
4.3
15.6
44
116
M60.9
ICD-10 Finland
Myositis, unspecified
47.9
15.3
18
*
Z46.8
ICD-10 Finland
Fitting and adjustment of other specified devices
12.4
14.6
26
23
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
3.2
14.5
70
265
N28
ICPC
Limited function/disability (N)
23.8
14.4
20
9
Z03.5
ICD-10 Finland
Observation for other suspected cardiovascular diseases
4.0
13.9
43
121
L99
ICPC
Musculoskeletal disease other
14.0
13.2
22
17
R52.2
ICD-10 Finland
Other chronic pain
6.0
13.1
24
43
M33.2
ICD-10 Finland
Polymyositis
73.4
12.7
14
*
Z50.1
ICD-10 Finland
Other physical therapy
5.1
12.7
28
60
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
3.2
12.5
59
219
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
2.7
12.5
85
386
R4130
NOMESCO Finland
Speech therapy
6.4
12.3
21
35
C10AX09
ATC
ezetimibe; oral
3.1
12.1
61
235
M62.9
ICD-10 Finland
Disorder of muscle, unspecified
68.0
11.7
13
*
N03AX16
ATC
[U] pregabalin
2.7
11.6
82
377
G71.06
ICD-10 Finland
Muscular dystrophy severe [Duchenne]
+∞
11.5
11
*
M47.2
ICD-10 Finland
Other spondylosis with radiculopathy
4.1
10.9
32
86
ZY020
NOMESCO Finland
Telephone, letter or other consultation without direct patient contact
4.0
10.9
33
91
N18
ICPC
Paralysis/weakness
11.9
10.7
19
17
R4110
NOMESCO Finland
Physiotherapy
2.4
10.5
97
504
I42.9
ICD-10 Finland
Cardiomyopathy, unspecified
16.9
10.5
16
10
G71.28
ICD-10 Finland
Other congenital myopathy
+∞
10.5
10
*
G71.25
ICD-10 Finland
Congenital muscular dystrophy NOS
+∞
10.5
10
*
Z01.8
ICD-10 Finland
Other specified special examinations
2.5
10.4
80
382
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
3.2
10.3
46
164
N29
ICPC
Neurological sympt/complt other
11.2
9.9
18
17
H02AB06
ATC
prednisolone; systemic
2.3
9.9
144
904
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
3.3
9.7
40
136
N03AF01
ATC
carbamazepine; oral, rectal
4.4
9.7
25
61
N03AX12
ATC
[U] gabapentin; oral
2.7
9.5
59
252
N07AA02
ATC
pyridostigmine; systemic
103.5
9.5
10
*
SPAT1215
SPAT
Assessment of need for medical rehabilitation
5.0
9.5
21
45
33030
ICD-8 Finland
Hereditary neuromuscular disorders, Progressive muscular dystrophy
+∞
9.4
9
*
NJ3DG
NOMESCO Finland
Very extensive MRI examination of extremities with high intensity magnet
+∞
9.4
9
*
L19
ICPC
Muscle symptom/complaint NOS
7.8
9.4
21
29
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
4.6
9.3
23
54
G47.3
ICD-10 Finland
Sleep apnoea
2.4
9.2
79
394
R4190
NOMESCO Finland
Nutritional therapy
4.1
9.2
26
68
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.3
9.0
89
472
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
2.3
9.0
88
465
G62.9
ICD-10 Finland
Polyneuropathy, unspecified
7.6
8.9
20
28
JDB10
NOMESCO Finland
Percutaneous gastrostomy
17.0
8.6
13
8
M03BX01
ATC
baclofen; systemic
9.0
8.4
17
20
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
2.9
8.4
43
165
R06.0
ICD-10 Finland
Dyspnoea
2.3
8.4
87
468
ZX120
NOMESCO Finland
Intravenous
3.0
8.4
39
142
RK110, ,
NOMESCO Finland
17.8
8.1
12
7
N02AX02
ATC
tramadol; systemic, rectal
2.1
8.1
123
768
Z71.8
ICD-10 Finland
Other specified counselling
2.1
8.0
100
579
Z50.9
ICD-10 Finland
Care involving use of rehabilitation procedure, unspecified
4.3
8.0
21
52
XG466
NOMESCO Finland
Sleep oxymetry
6.5
7.7
19
31
TJD20
NOMESCO Finland
Change of gastrostomy tube
19.0
7.7
11
6
TAW99
NOMESCO Finland
Other minor neurosurgical procedure
25.8
7.6
10
*
Z3229
NOMESCO Finland
Other healthcare associate professional
3.0
7.5
36
133
Z99.1
ICD-10 Finland
Dependence on respirator
82.2
7.5
8
*
M41.4
ICD-10 Finland
Neuromuscular scoliosis
82.2
7.5
8
*
SPAT1216
SPAT
Assessment of functional ability
2.6
7.4
46
195
N02BF02
ATC
pregabalin; oral
3.6
7.4
25
74
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
3.6
7.4
25
74
33098
ICD-8 Finland
Hereditary neuromuscular disorders, Alii definiti
+∞
7.3
7
*
3591A
ICD-9 Finland
Muscular dystrophies and other myopathies, Hereditary progressive muscular dystrophy
+∞
7.3
7
*
TAB00
NOMESCO Finland
Lumbar puncture
3.7
7.2
23
66
XF400
NOMESCO Finland
ECG with 12 standard connections
2.4
7.1
54
253
Z2446
NOMESCO Finland
Social worker
2.9
7.0
36
138
XA402
NOMESCO Finland
ENMG
6.1
7.0
18
31
Z3231
NOMESCO Finland
Registered nurse
2.1
7.0
92
539
SPAT1153
SPAT
Removal of sutures
2.1
6.9
88
508
NA7EA
NOMESCO Finland
Scoliosis X-ray examination
9.7
6.9
13
14
R60.9
ICD-10 Finland
Oedema, unspecified
4.1
6.8
19
49
SPAT1220
SPAT
Assessment of need for rehabilitation and/or rehabilitation plan
3.4
6.8
25
79
RD210, ,
NOMESCO Finland
6.2
6.7
17
29
M51.3
ICD-10 Finland
Other specified intervertebral disc degeneration
3.2
6.7
27
90
RF410, ,
NOMESCO Finland
12.7
6.6
11
9
R42
ICD-10 Finland
Dizziness and giddiness
2.2
6.5
66
348
K59.09
ICD-10 Finland
Constipation, unspecified
3.3
6.5
25
81
I42.0
ICD-10 Finland
Dilated cardiomyopathy
7.7
6.5
14
19
ZYC01
NOMESCO Finland
Remote contact by phone
3.1
6.4
27
93
R03BA08
ATC
ciclesonide; inhalant
2.9
6.4
30
110
N06AX21
ATC
duloxetine; oral
2.5
6.3
42
184
N02BF01
ATC
gabapentin; oral
2.9
6.3
31
116
Z09.0
ICD-10 Finland
Follow-up examination after surgery for other conditions
3.3
6.3
24
77
Z03.80
ICD-10 Finland
Observation for other suspected diseases and conditions
5.3
6.3
18
36
SPAT1231
SPAT
Assessment of adjustments needed in living environment
7.3
6.3
14
20
G70.0
ICD-10 Finland
Myasthenia gravis
+∞
6.3
6
*
3599X
ICD-9 Finland
Muscular dystrophies and other myopathies, Myopathy, unspecified
+∞
6.3
6
*
QDA99
NOMESCO Finland
Other local destruction of skin of lower limb
27.4
6.3
8
*
WYA30
NOMESCO Finland
Treatment of a patient needing special arrangements
2.7
6.1
34
136
RF420, ,
NOMESCO Finland
8.9
6.1
12
14
GD1AA
NOMESCO Finland
Thorax X-ray examination
1.9
6.1
123
828
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
47
14
40.35
75.11
1.5
1.6
7.40
8.33
u/l
0.11
40
14
182
608
6.98
55.59
4.3
2.1
1156.05
166.60
u/l
2.22
176
569
122
532
3.34
20.85
3.8
3.4
1251.79
1178.01
ng/l
0.04
113
450
26
15
19.01
17.30
1.3
1.1
—
—
—
0
0
177
1033
3.03
17.12
8.4
8.1
1.22
1.21
mmol/l
0.05
160
887
164
953
2.81
15.39
8.6
7.3
1.21
1.22
mmol/l
0.37
157
875
58
217
3.12
12.07
6.6
5.9
2.18
1.90
mmol/l
0.28
51
180
58
221
3.06
11.68
6.6
5.9
6.21
5.78
kpa
2.51
58
215
148
901
2.40
11.41
5.7
5.3
36.18
36.19
g/l
0.01
143
847
43
143
3.38
10.80
3.3
3.4
136.16
194.29
ng/l
0.44
37
129
130
770
2.31
10.41
4.3
3.0
—
—
—
0
0
142
882
2.27
10.04
3.8
2.4
77.72
76.35
nmol/l
0.21
135
789
60
263
2.64
9.18
8.7
7.5
104.35
104.40
mmol/l
0.03
60
263
220
1679
2.60
9.16
10.8
7.5
81.41
82.61
u/l
0.14
211
1577
48
192
2.82
8.74
5.5
5.7
4.62
4.67
kpa
0.07
48
187
105
612
2.16
8.32
3.6
3.0
0.55
0.39
e6/l
0.24
86
455
155
1048
2.11
8.30
4.8
3.4
0.00
0.00
estimate
-0.00
33
180
27
79
3.68
8.18
1.3
1.3
0.20
3.83
u/ml
—
5
7
77
399
2.30
8.11
4.2
3.7
76.78
257.23
ng/l
1.57
67
295
153
1039
2.08
7.99
6.1
4.6
0.00
0.00
estimate
-0.00
34
196
177
1269
2.12
7.98
7.4
5.4
6.10
6.61
mmol/l
4.91
169
1188
53
235
2.56
7.85
8.0
9.9
1.41
1.36
mmol/l
0.02
42
200
21
54
4.13
7.58
1.8
1.2
—
—
—
0
0
162
1143
2.03
7.39
7.3
6.8
12.78
12.43
umol/l
0.09
154
1081
10
5
20.67
7.18
1.1
1.0
—
—
—
0
0
150
1045
1.97
6.93
4.9
3.4
0.00
0.00
estimate
0.50
33
204
112
706
1.99
6.92
3.3
3.4
2.38
2.36
mmol/l
1.20
102
626
43
185
2.57
6.74
5.1
4.8
5.36
5.08
kpa
1.26
43
176
41
178
2.53
6.30
5.2
4.9
1.78
1.39
mmol/l
0.23
36
131
20
57
3.71
6.29
1.5
1.5
0.21
0.06
iu/ml
—
7
12
63
331
2.17
6.28
2.0
2.0
—
—
—
0
0
177
1337
1.92
6.09
11.5
10.2
4.03
3.97
e9/l
0.14
161
1161
115
761
1.88
5.95
2.2
1.8
89.45
97.68
pmol/l
1.31
58
375
19
55
3.64
5.84
2.9
2.7
26.36
24.67
mmol/l
0.79
19
55
203
1617
2.00
5.83
6.1
4.2
11.54
10.53
mm/h
0.52
191
1483
23
76
3.21
5.80
2.1
2.3
—
—
—
0
0
38
167
2.48
5.69
2.2
2.6
67.78
66.93
ml/min/173m2
—
9
70
66
367
2.05
5.63
3.3
2.7
2.47
2.44
mmol/l
1.42
60
314
10
11
9.38
5.33
3.7
3.6
87.60
151.75
ug/l
—
10
11
62
345
2.03
5.26
2.8
2.8
2.46
1.97
e6/l
0.22
40
185
117
810
1.78
5.02
5.3
3.4
—
—
—
0
0
65
374
1.97
5.00
3.0
2.6
0.83
0.79
e6/l
0.04
44
212
21
72
3.08
4.99
3.2
2.8
—
—
—
0
0
113
778
1.77
4.92
4.4
3.5
58.76
34.52
ng/l
0.88
92
518
26
103
2.68
4.79
3.3
4.9
1.89
1.26
%
1.31
26
103
75
459
1.87
4.78
2.1
2.2
2.42
1.25
mg/l
0.43
58
364
25
99
2.68
4.61
3.4
4.9
0.66
0.66
%
0.03
25
99
45
237
2.08
4.39
1.8
2.0
—
—
—
0
0
8
9
9.11
4.31
1.4
1.0
—
—
—
0
0
14
34
4.28
4.27
1.1
1.1
—
—
—
0
0
97
661
1.73
4.26
2.7
2.6
54.49
56.85
u/l
0.34
90
614
11
21
5.41
4.19
1.1
1.0
—
—
—
0
0
32
151
2.27
4.10
1.4
1.4
369.30
346.38
u/ml
0.03
32
136
13
32
4.21
3.96
1.2
1.1
—
—
—
0
0
79
519
1.73
3.90
2.8
2.4
3.03
3.14
mg/l
0.13
72
442
20
77
2.72
3.90
1.7
2.2
2.22
4.03
ug/l
0.20
20
70
9
15
6.16
3.84
4.8
3.6
35.67
25.53
umol/l
—
9
15
56
337
1.83
3.70
2.9
2.6
30.32
29.67
s
0.46
56
331
22
92
2.51
3.66
3.9
3.3
53.38
52.15
%
0.08
22
92
230
2017
1.89
3.65
18.3
11.7
96.24
84.64
ml/min/173m2
5.91
202
1635
35
181
2.07
3.58
9.8
8.8
25.88
25.05
mmol/l
0.58
35
181
21
88
2.50
3.49
1.4
1.6
—
—
—
0
0
80
544
1.67
3.44
6.1
3.6
0.00
0.02
estimate
0.68
33
191
11
27
4.20
3.43
1.5
1.2
—
—
—
0
0
11
27
4.20
3.43
1.5
1.2
—
—
—
0
0
103
749
1.60
3.38
5.6
3.7
52.14
33.47
u/l
1.83
98
712
226
1986
1.80
3.36
5.3
5.3
38.56
39.46
mmol/mol
0.69
213
1868
11
28
4.05
3.32
1.5
1.2
—
—
—
0
0
11
28
4.05
3.32
1.5
1.2
—
—
—
0
0
11
28
4.05
3.32
1.5
1.2
—
—
—
0
0
198
1684
1.64
3.28
4.9
3.8
15.19
14.61
pmol/l
2.19
186
1528
41
233
1.89
3.23
1.8
1.9
—
—
—
0
0
140
1102
1.56
3.22
9.5
6.9
56.41
55.67
%
0.32
140
1038
26
126
2.18
3.14
1.6
1.3
—
—
—
0
0
17
68
2.60
3.10
1.4
2.6
3.17
2.93
g/l
0.64
17
63
17
68
2.60
3.10
1.2
2.6
9.87
10.08
g/l
0.09
17
63
248
2259
2.07
3.09
21.6
13.0
19.63
22.13
mg/l
0.72
213
1722
18
75
2.50
3.04
1.4
2.5
3.51
3.56
g/l
0.12
18
70
18
75
2.50
3.04
1.4
2.5
7.62
7.21
g/l
0.60
18
70
18
75
2.50
3.04
1.4
2.5
—
—
—
0
0
141
1121
1.53
3.04
9.6
7.1
28.67
29.40
%
0.34
141
1058
55
349
1.72
3.02
2.0
1.6
1404.36
1227.67
nmol/l
0.47
43
264
13
46
2.92
2.96
1.3
2.0
—
—
—
0
0
13
46
2.92
2.96
1.3
2.0
—
—
—
0
0
227
2025
1.72
2.85
5.8
4.4
1.94
1.88
mu/l
0.45
216
1855
30
160
1.98
2.84
1.7
1.2
226.52
188.63
iu/ml
—
9
66
15
59
2.63
2.84
1.3
2.7
40.77
38.98
g/l
0.65
15
54
119
925
1.51
2.78
17.4
11.0
1.26
1.20
inr
0.31
40
261
9
24
3.84
2.69
1.3
1.8
—
—
—
0
0
9
24
3.84
2.69
1.3
1.8
—
—
—
0
0
9
24
3.84
2.69
1.3
1.8
—
—
—
0
0
12
41
3.01
2.65
7.0
2.7
5.47
4.99
kpa
1.08
12
41
66
456
1.59
2.60
1.8
1.5
22.92
22.03
nmol/l
0.17
57
379
119
938
1.48
2.54
3.6
2.8
123.36
108.46
ug/l
0.30
113
873
9
26
3.54
2.50
1.1
2.1
—
—
—
0
0
17
76
2.32
2.50
2.1
2.1
—
—
—
0
0
7
16
4.46
2.49
1.0
1.0
—
—
—
0
0
8
21
3.89
2.48
1.4
1.2
—
—
—
0
0
26
139
1.96
2.46
6.0
5.3
24.48
24.51
mmol/l
0.02
26
134
6
12
5.08
2.41
1.5
1.9
—
—
—
0
0
6
12
5.08
2.41
1.5
1.9
—
—
—
0
0
14
58
2.49
2.41
3.6
4.4
28.43
36.08
umol/l
1.16
14
52
73
525
1.53
2.40
2.7
3.1
338.95
5980.21
umol/l
1.98
66
456
10
34
3.01
2.30
1.6
1.9
—
—
—
0
0
23
121
1.98
2.29
4.0
3.4
4.70
4.65
pmol/l
0.09
23
108
7
18
3.96
2.26
3.0
1.6
2.29
3.02
mg/l
—
7
18
15
67
2.31
2.22
1.5
2.0
—
—
—
0
0
6
14
4.36
2.16
1.0
1.0
—
—
—
0
0
15
68
2.28
2.15
1.3
2.0
—
—
—
0
0
6
15
4.06
2.05
1.0
1.1
—
—
—
0
0
21
112
1.95
2.02
1.4
1.7
—
—
—
0
0
13
57
2.34
2.01
1.6
1.6
—
—
—
0
0
14
64
2.25
1.98
1.6
1.5
—
—
—
0
0
10
39
2.62
1.96
1.7
1.0
53.00
58.89
iu/ml
—
5
9
8
27
3.02
1.95
2.9
2.6
558.25
576.04
e6/l
—
8
27
6
16
3.81
1.94
1.0
1.3
1.90
1.69
mmol/l
—
6
16
6
16
3.81
1.94
2.0
1.3
—
—
—
0
0
15
72
2.15
1.90
2.0
1.9
—
—
—
0
0
7
22
3.24
1.89
2.7
3.5
—
—
—
0
0
14
66
2.18
1.85
1.4
1.4
258.00
310.36
ug/g
—
9
37
6
17
3.58
1.84
2.0
1.2
—
79.00
—
0
6
9
35
2.62
1.82
1.0
1.9
—
—
—
0
0
7
23
3.10
1.81
1.3
2.2
24.21
18.71
ug/l
—
7
23
7
24
2.97
1.73
1.0
1.0
—
—
—
0
0
13
62
2.15
1.68
1.7
1.4
100.71
281.34
u/ml
—
7
32
48
342
1.49
1.64
1.2
1.3
3.47
6.77
u/ml
0.61
26
133
65
492
1.42
1.63
3.1
2.4
—
—
—
0
0
13
64
2.08
1.57
2.3
1.2
—
—
—
0
0
5
15
3.37
1.53
1.0
1.8
—
—
—
0
0
13
65
2.05
1.51
1.5
1.3
—
—
—
0
0
72
565
1.37
1.46
1.3
1.4
0.75
1.38
u/ml
0.94
12
152
40
282
1.49
1.45
7.5
4.1
6.03
8.89
umol/l
1.02
30
252
5
16
3.16
1.44
1.2
3.1
—
—
—
0
0
5
16
3.16
1.44
1.2
3.1
—
—
—
0
0
9
39
2.35
1.44
1.4
1.1
—
—
—
0
0
20
119
1.73
1.42
1.2
1.6
13.11
25.29
iu/l
1.18
13
96
9
40
2.29
1.41
1.0
2.0
—
—
—
0
0
9
40
2.29
1.41
1.7
1.4
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
11
53
2.12
1.40
4.0
3.2
0.32
0.31
u/ml
—
5
30
9
41
2.23
1.38
3.8
6.4
—
3607.14
—
0
7
48
355
1.43
1.37
1.3
1.3
20.44
34.00
iu/ml
—
9
129
114
967
1.31
1.36
2.9
2.6
—
—
—
0
0
12
217
0.53
1.33
1.2
1.7
—
—
—
0
0
8
34
2.39
1.30
1.0
2.1
—
—
—
0
0
8
35
2.32
1.28
1.0
2.0
—
—
—
0
0
8
35
2.32
1.28
1.0
2.0
—
—
—
0
0
6
25
2.43
1.25
1.2
1.5
—
—
—
0
0
5
19
2.66
1.22
2.4
3.5
—
—
—
0
0
34
241
1.47
1.21
13.2
7.8
—
—
—
0
0
10
50
2.04
1.18
1.2
2.1
—
—
—
0
0
10
50
2.04
1.18
1.0
1.9
—
—
—
0
0
63
504
1.32
1.12
4.4
3.9
23.19
22.00
%
0.20
22
216
8
41
1.98
1.09
1.8
1.3
—
—
—
0
0
8
41
1.98
1.09
1.8
1.3
—
—
—
0
0
28
196
1.48
1.07
1.7
4.4
29.95
28.22
ug/l
0.02
19
154
23
155
1.53
1.05
2.0
1.5
—
—
—
0
0
5
23
2.19
0.98
1.4
1.3
—
—
—
0
0
13
77
1.72
0.97
1.4
1.2
—
—
—
0
0
75
628
1.27
0.95
4.3
4.2
1.65
1.87
ug/l
0.41
70
561
6
28
2.17
0.92
1.7
1.4
—
—
—
0
0
6
29
2.09
0.90
1.2
1.0
—
—
—
0
0
13
79
1.68
0.89
1.4
1.2
—
—
—
0
0
220
2089
1.27
0.83
4.6
4.2
5.77
5.88
mmol/l
0.75
206
1927
6
32
1.89
0.82
1.8
1.4
—
—
—
0
0
9
57
1.60
0.72
2.1
1.4
—
—
—
0
0
5
27
1.87
0.69
2.0
1.9
—
—
—
0
0
259
2530
1.46
0.65
31.4
19.5
40.65
40.59
%
0.06
250
2391
259
2531
1.45
0.64
30.6
19.4
4.58
4.55
e12/l
0.43
254
2462
68
591
1.20
0.61
3.4
3.7
8.36
8.41
mg/mmol
0.00
51
386
6
36
1.68
0.57
1.2
3.1
18.67
28.79
u/ml
—
6
36
57
492
1.20
0.55
1.7
1.6
—
—
—
0
0
6
39
1.55
0.53
1.2
1.1
—
—
—
0
0
7
45
1.57
0.49
2.7
3.0
57.71
58.60
%
—
7
45
7
49
1.44
0.46
2.0
1.7
—
—
—
0
0
0
16
0.00
0.41
0.0
1.2
—
—
—
0
0
5
35
1.44
0.39
1.2
2.1
—
—
—
0
0
0
19
0.00
0.39
0.0
1.7
—
—
—
0
0
9
66
1.38
0.39
1.4
1.3
—
—
—
0
0
5
36
1.40
0.38
1.0
1.2
10.62
12.47
u/l
—
5
30
222
2158
1.15
0.38
5.0
4.3
4.69
4.70
mmol/l
0.08
212
2026
12
90
1.35
0.36
1.6
1.8
—
—
—
0
0
6
42
1.44
0.36
1.5
1.2
—
—
—
0
0
6
42
1.44
0.36
1.7
1.5
—
—
—
0
0
6
43
1.40
0.35
1.2
1.9
—
—
—
0
0
213
2071
1.13
0.33
4.5
3.8
1.38
1.29
mmol/l
0.70
202
1919
160
1538
1.10
0.29
5.0
3.4
60.23
47.74
u/l
0.57
151
1460
224
2193
1.12
0.26
5.3
4.7
2.83
2.81
mmol/l
0.12
213
2039
9
76
1.19
0.25
1.3
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
4.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
0.58
—
0
7
5
43
1.17
0.21
1.2
1.1
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
23
203
1.15
0.20
3.9
3.2
—
—
—
0
0
57
607
0.92
0.18
2.0
1.7
1.53
1.42
mmol/l
0.37
49
518
7
59
1.19
0.18
1.1
2.3
—
—
—
0
0
160
1558
1.07
0.17
3.2
3.2
—
—
—
0
0
5
67
0.74
0.17
1.6
1.5
—
—
—
0
0
8
70
1.15
0.16
1.0
1.1
—
0.89
—
0
8
8
70
1.15
0.16
1.3
1.4
—
—
—
0
0
26
235
1.12
0.16
1.8
1.9
—
—
—
0
0
29
264
1.11
0.16
1.8
2.0
—
—
—
0
0
12
140
0.85
0.15
1.0
1.1
—
—
—
0
0
39
363
1.09
0.15
2.8
2.8
0.69
0.74
ug/l
0.12
24
225
9
106
0.84
0.13
1.2
2.0
—
—
—
0
0
29
313
0.92
0.12
1.6
1.4
—
—
—
0
0
217
2146
1.05
0.10
4.9
4.2
1.46
1.46
mmol/l
0.03
205
2000
5
48
1.04
0.09
1.0
1.4
—
—
—
0
0
5
60
0.83
0.08
1.2
1.4
—
—
—
0
0
15
137
1.10
0.07
1.3
1.3
—
—
—
0
0
12
128
0.93
0.02
1.3
2.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
5
51
0.98
-0.00
2.4
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.5
—
8.10
—
0
8
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.8
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
10.38
—
0
8
Mortality – FinRegistry
↥Association
Association between endpoint G6_MUSCOTHUNS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_MUSCOTHUNS | 2.962 [2.19, 4.0] | < 0.001 |
| Birth year | 0.992 [0.98, 1.0] | 0.081 |
During the follow-up period (1.1.1998 — 31.12.2019), 136 out of 719 females with G6_MUSCOTHUNS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_MUSCOTHUNS | 2.651 [2.11, 3.34] | < 0.001 |
| Birth year | 0.987 [0.98, 1.0] | 0.024 |
During the follow-up period (1.1.1998 — 31.12.2019), 181 out of 773 males with G6_MUSCOTHUNS died.
Mortality risk
Mortality risk for people of age
years, who have G6_MUSCOTHUNS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.252% | 0.384% |
| 5 | 1.66% | 2.69% |
| 10 | 3.948% | 6.826% |
| 15 | 7.418% | 13.381% |
| 20 | 12.42% | 22.845% |
Relationships between endpoints
↥Index endpoint: G6_MUSCOTHUNS – Other and unspecified primary disorders of muscles
GWS hits: 11
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data